News

Eastern United States has the highest arthritis rates


 

FROM MORBIDITY AND MORTALITY WEEKLY REPORT

References

The prevalence of arthritis tended to be higher in eastern U.S. states than in western states in 2011, according to a report from the Centers for Disease Control and Prevention.

All seven states with an arthritis rate below 22% were located west of the Mississippi River, with Hawaii having the lowest rate at 18.2%, followed by Utah (19.8%) and Texas (20.2%). The District of Columbia, which is in the East, had an arthritis rate of 20.9%.

Prevalence of adults diagnosed with arthritis, 2011

Prevalence of adults diagnosed with arthritis, 2011

The eight states with an arthritis rate greater than 29% were all east of the Mississippi, with West Virginia having the highest prevalence (35.9%), followed by Kentucky (31.9%) and Michigan (31.0%), according to the report (MMWR 2014;63[SS09]:1-149).

Of 198 reported metropolitan and micropolitan statistical areas (MMSAs), 29 had an arthritis prevalence lower than 20%. Lawrence, Kan., had the lowest rate at 13.5%. Of the 29, only Atlanta; Knoxville, Tenn.; and Raleigh, N.C., are located entirely east of the Mississippi River. Kingsport-Bristol, in Tennessee and Virginia, had the highest arthritis rate at 37%. Of the 16 MMSAs with an arthritis rate greater than 30%, North Platte, Neb., was the only one west of the Mississippi, according to data from the Behavioral Risk Factor Surveillance System.

lfranki@frontlinemedcom.com

Recommended Reading

Biosimilars poised to make biologics more routine
MDedge Rheumatology
Inflammatory rheumatic diseases raise venous thromboembolism risk
MDedge Rheumatology
RA patients’ readmission rates after joint replacement are rising
MDedge Rheumatology
Biomarkers identify RA patients at risk of lung disease
MDedge Rheumatology
Hand exercise program worthwhile, cost effective in RA patients
MDedge Rheumatology
Tocilizumab and tofacitinib increase lipids in RA patients
MDedge Rheumatology
FDA approves new abuse-prevention labeling for extended-release Embeda
MDedge Rheumatology
In psoriasis, is pushing for PASI 90 really worthwhile?
MDedge Rheumatology
ACR 2010 criteria for fibromyalgia critiqued
MDedge Rheumatology
Disease activity, not lipid levels, appear to affect CV risk with tocilizumab
MDedge Rheumatology